Deletions removing the last exon of TACSTD1 constitute a distinct class of mutations predisposing to Lynch syndrome

Several different genetic alterations in the etiology of Lynch syndrome (hereditary nonpolyposis colorectal cancer [HNPCC]) are known, mostly point mutations and genomic rearrangements in 1 of at least 3 mismatch‐repair (MMR) genes. However, no susceptibility factor has yet been identified in a significant part (30–50%) of clinicopathologically well‐defined HNPCC families, suggesting the presence of other predisposing mechanisms. In a set of probands from 27 Lynch syndrome families who lacked evidence of a germline mutation in either the MSH2 or MLH1 gene, we performed genomic deletion screening with the use of multiplex ligation‐dependent probe amplification (MLPA) and sequencing. We used immunohistochemistry (IHC) and microsatellite instability (MSI) analyses on samples of the probands of all families. Comparative analysis of mRNA transcripts was performed on blood leukocyte–derived samples from mutation carriers and noncarrier controls. We report that large germline deletions encompassing the last exons of the TACSTD1 gene, upstream of MSH2, cosegregate with the HNPCC phenotype in 19% (5/27) of families tested. The tumors of the carriers show high‐level MSI and MSH2 protein loss. We show that these deletions, by removing the transcriptional termination sequences of the upstream gene, give rise to multiple TACSTD1/MSH2 fusion transcripts. Our results provide evidence that deletions removing the last exon of TACSTD1 constitute a distinct class of mutations predisposing to Lynch syndrome. Thus, analysis of the 3′ region of the TACSTD1 gene should be included in the routine mutation screening protocols for HNPCC. Hum Mutat 30, 197–203, 2009. © 2009 Wiley‐Liss, Inc.

[1]  M. Harmsen,et al.  Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule. , 2007, The American journal of pathology.

[2]  E. Oláh,et al.  Germline MLH1 and MSH2 mutational spectrum including frequent large genomic aberrations in Hungarian hereditary non-polyposis colorectal cancer families: implications for genetic testing. , 2007, World journal of gastroenterology.

[3]  K. Kinzler,et al.  Lynch syndrome (hereditary nonpolyposis colorectal cancer) diagnostics. , 2007, Journal of the National Cancer Institute.

[4]  S. Chattopadhyay,et al.  MARs and MARBPs , 2007, Chromatin and Disease.

[5]  M. Kloor,et al.  Genotype-phenotype comparison of German MLH1 and MSH2 mutation carriers clinically affected with Lynch syndrome: a report by the German HNPCC Consortium. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  S. Leung,et al.  Heritable germline epimutation of MSH2 in a family with hereditary nonpolyposis colorectal cancer , 2006, Nature Genetics.

[7]  Z. Szentirmay,et al.  Pedigree and genetic analysis of a novel mutation carrier patient suffering from hereditary nonpolyposis colorectal cancer. , 2006, World journal of gastroenterology.

[8]  P. Møller,et al.  Molecular characterization of the spectrum of genomic deletions in the mismatch repair genes MSH2, MLH1, MSH6, and PMS2 responsible for hereditary nonpolyposis colorectal cancer (HNPCC) , 2005, Genes, chromosomes & cancer.

[9]  S. Thibodeau,et al.  Characterization of hMLH1 and hMSH2 gene dosage alterations in Lynch syndrome patients. , 2005, Gastroenterology.

[10]  A. Lindblom,et al.  The 5′ region of the MSH2 gene involved in hereditary non‐polyposis colorectal cancer contains a high density of recombinogenic sequences , 2005, Human mutation.

[11]  Thomas Werner,et al.  MatInspector and beyond: promoter analysis based on transcription factor binding sites , 2005, Bioinform..

[12]  K. Shearwin,et al.  Transcriptional interference--a crash course. , 2005, Trends in genetics : TIG.

[13]  H. Lynch,et al.  Hereditary colorectal cancer-part II. , 2005, Current problems in surgery.

[14]  D. Kleinjan,et al.  Long-range control of gene expression: emerging mechanisms and disruption in disease. , 2005, American journal of human genetics.

[15]  L. Maquat Nonsense-mediated mRNA decay: splicing, translation and mRNP dynamics , 2004, Nature Reviews Molecular Cell Biology.

[16]  A. Lindblom,et al.  Screening for genomic rearrangements of the MMR genes must be included in the routine diagnosis of HNPCC , 2004, Journal of Medical Genetics.

[17]  David I. K. Martin,et al.  Germline epimutation of MLH1 in individuals with multiple cancers , 2004, Nature Genetics.

[18]  A. de la Chapelle,et al.  Molecular analysis of hereditary nonpolyposis colorectal cancer in the United States: high mutation detection rate among clinically selected families and characterization of an American founder genomic deletion of the MSH2 gene. , 2003, American journal of human genetics.

[19]  D. Zwijnenburg,et al.  Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. , 2002, Nucleic acids research.

[20]  T. Werner,et al.  In silico prediction of scaffold/matrix attachment regions in large genomic sequences. , 2002, Genome research.

[21]  S. Antonarakis,et al.  Nomenclature for the description of human sequence variations , 2001, Human Genetics.

[22]  M. King,et al.  Prevalence of founder BRCA1 and BRCA2 mutations among breast and ovarian cancer patients in Hungary , 2000, International journal of cancer.

[23]  S. Antonarakis,et al.  Mutation nomenclature extensions and suggestions to describe complex mutations: A discussion , 2000 .

[24]  S Srivastava,et al.  A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. , 1998, Cancer research.

[25]  K. Maruyama,et al.  Promoter analysis of the human mismatch repair gene hMSH2. , 1998, Gene.

[26]  B. Ponder,et al.  Analysis of BRCA1 and BRCA2 mutations in Hungarian families with breast or breast-ovarian cancer. , 1997, American journal of human genetics.

[27]  B. Ponder,et al.  A breast/ovarian cancer patient with germline mutations in both BRCA1 and BRCA2 , 1997, Nature Genetics.

[28]  Marvin B. Shapiro,et al.  RNA splice junctions of different classes of eukaryotes: sequence statistics and functional implications in gene expression. , 1987, Nucleic acids research.

[29]  N. Proudfoot,et al.  Alpha‐thalassaemia caused by a poly(A) site mutation reveals that transcriptional termination is linked to 3′ end processing in the human alpha 2 globin gene. , 1986, The EMBO journal.

[30]  S. Goodbourn,et al.  α-Thalassaemia caused by a polyadenylation signal mutation , 1983, Nature.